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Abstract  20 
This work reports on the variation in wastewater treatment works (WwTW) influent concentrations of 21 
a wide variety of active pharmaceutical ingredients (APIs), their removal efficiency, effluent 22 
concentrations and potential risks to the aquatic environment. The research is based on data generated 23 
from two large UK-wide WwTW monitoring programmes. Taking account of removal of parent 24 
compound from the aqueous phase during treatment in combination with estimates of dilution 25 
available it is possible to prioritise the APIs of greatest risk of exceeding estimates of predicted no 26 
effect concentrations (PNEC) in receiving waters for all WwTW in the UK. The majority of 27 
substances studied were removed to a high degree, although with significant variation, both within 28 
and between WwTW. Poorer removal (between influent and effluent) was observed for 29 
ethinyloestradiol, diclofenac, propranolol, the macrolide antibiotics, fluoxetine, tamoxifen and 30 
carbamazepine. All except the last two of these substances were present in effluents at concentrations 31 
higher than their respective estimated PNEC (based on measurement of effluents from 45 WwTW on 32 
20 occasions). Based on available dilution data as many as 890 WwTW in the UK (approximately 33 
13% of all WwTW) may cause exceedances of estimated riverine PNECs after mixing of their 34 
effluents with receiving waters. The overall degree of risk is driven by the toxicity value selected, 35 
which in itself is controlled by the availability of reliable and relevant ecotoxicological data and 36 
consequently the safety factors applied. The dataset and discussion, provides information to assist in 37 
the future management of these types of chemicals.     38 
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1. INTRODUCTION 45 
 46 
The use and environmental prevalence of pharmaceuticals increases on an annual basis due to a 47 
variety of reasons including the widening array of medical treatments available, greater availability of 48 
medicines across the world, affordability, population growth, population ageing (in some countries)  49 
and changing perspectives towards, for example, pain (Jelic et al., 2011). Active Pharmaceutical 50 
Ingredients (API) are detected throughout the environment in water, soil, sediment, sludge as well as 51 
in drinking waters in some countries (Kasprzyk-Hordern et al., 2008; Zorita et al., 2009; Wahlberg et al., 52 
2011; Jones et al., 2014; Lees et al., 2016). Although the mere presence of pharmaceutical is not 53 
always associated with harm to the environment or human health, concerns are rising associated with 54 
antimicrobial resistance and chronic impacts on biodiversity including endocrine disrupting effects on 55 
fish (Levado et al, 2004; Jobling et al., 2005; Tyler et al., 2008). The main source of occurrence of 56 
APIs in the river environment is from human use of pharmaceuticals, via the continuous discharge of 57 
effluent from the Wastewater Treatment Works (WwTW) (Gardner et al., 2012; Melvin et al., 2016). 58 
Hence, investigating the occurrence, fate and risk of APIs is currently of great interest to regulators 59 
and the water industry alike, with a focus to better understand the loadings entering WwTW and the 60 
observed within and between works variation in removal efficiencies and concentrations often 61 
observed for APIs (Gardner, 2013). 62 
 63 
The range of concentrations found for pharmaceuticals studied in the UK is similar to that observed in 64 
continental Europe as well as in the USA (Kolpin et al., 2002; Ashton et al., 2004; Hope et al., 2012; 65 
Bradley et al., 2016; Burns et al., 2017). Table 1 provides examples of other reported data for APIs 66 
determined as part of this research, rather than a complete list of all APIs detected in effluent and 67 
receiving waters. Other studies have also shown that there is a clear association between the number 68 
of pharmaceuticals used in a society and the levels of API found in receiving water bodies ranging 69 
from API concentration of typically less than 100 ng/l in the surface and groundwater and below 50 70 
ng/l in treated drinking water (WHO, 2011; Furlong et al., 2017) to higher levels reported adjacent to 71 
production facilities (Phillips et al., 2010). Predicted no effect concentrations (PNECs) have been 72 
reported for some APIs below 1 ng/l and APIs such as diclofenac (CAS 15307-79-6), 17-beta-73 
estradiol (E2) (CAS 50-28-2) and 17-alpha-ethinylestradiol (EE2) (CAS 57-63-6) are on the European 74 
Water Framework Directive (WFD) ‘watch list’ (EU, 2013). This requires member states to gather 75 
monitoring data in order to assess risk to the environment, leading to significant sources of APIs 76 
needing to be quantified and factors controlling the discharge of APIs carefully considered along with 77 
impacts on receiving water ecology, including effects of mixtures (Bound and Voulvoulis, 2006). 78 
79 
Table 1.  Average aquatic concentrations for APIs of interest to this research found in river 80 
                             water, as well as usage, excretion and removal in WwTW. 81 
 82 
API Therapeutic Class Upstream  
(µg/l) 
Influent 
(µg/l) 
Effluent 
(µg/l) 
WwTW 
removal 
(%) 
Down 
stream 
(µg/l) 
UK 
consumption 
(ton/year), 
2009 and 
2011 
Excreted 
unchanged 
compound 
(%) 
Aspirin 
(acetylsalicylic 
acid) 
Anti-
inflammatory/analgesics 
NA NA NA NA <0.0005b 130d <1b 
Atenolol Beta blocker NA NA NA NA 0-0.56
b 28e 90f 
Azithromycin Antibiotic NA 0.163
l 0.030l 90l NA NA NA 
Carbamazepine Antiepileptic NA 2.593
b 3.117b NDb 0.0005-
0.356b 
48e 3b 
Ciprofloxacin Antibiotic NA 1.090
l 0.052l 97l NA NA NA 
Clarithromycin Antibiotic NA 0.524
l 0.092l 91l NA NA NA 
Diclofenac Anti-inflammatory <0.020
a 0.107-
0.981c 
0.599a 70-92c 0.154a 28e 15f 
Erythromycin Antibiotic <0.010
a 2.0k 0.109a 25-91i 0.159a 3d 25f 
Oestrogen 
(E1) 
Natural hormone NA 0.042g 0.011-
0.025g 
58-96g NA NA NA 
Oestradiol 
(E2) 
Contraceptive NA 0.016g 0.0013-
0.0039g 
89-96g NA NA NA 
Ethinylestradiol 
(EE2) 
Contraceptive NA 0.0017g 0.00033-
0.00078g 
53-71g NA NA NA 
Fluoxetine Psychiatric drugs NA 0.070
k 0.023j 33-100h NA 6.4m NA 
Ibuprofen Analgesic 0.432
a 14.0k 4.201a 90-100i 1.105a 258e 10f 
Oxytetracycline Antibiotic NA 1.09
l 0.029l 99l NA NA NA 
Ofloxacin Antibiotic NA 0.081
l 0.023l 89l NA NA NA 
Propranolol Antihypertensive 0.010
a 0.542b 0.093a 
0.388b 
28b 0.041a 15e <0.5b 
Tamoxifen Anti-cancer <0.010
a 0.0002-
0.015c 
<0.010a 32-45c <0.010a NA NA 
 83 
ND = not detected; NA = not available. 
a
Ashton et al., 2006; 
b
Kasprzyk-Hordern et al., 2008; 
c
Zhou et al., 2009; 84 
d
2006 sales data for Wales; Kasprzyk-Hordern et al., 2008;
 e
IMS figure on active ingredient sales; 
f 
WHO, 2011; 85 
g
Heffley et al., 2014; 
h
Clara et al., 2005; 
i
Li et al., 2014;  
j
Gardner et al., 2012; 
k
Gardner et al., 2013;
l
 Singer et 86 
al., 2014; 
m 
Boxall et al., 2014 87 
 88 
Many countries have therefore started monitoring programs to investigate the exposure of APIs in 89 
order to gain a better understanding of their sources, fate and risk (Falås et al., 2012). The Chemical 90 
Investigation Program (CIP) in the UK is a large ongoing investment being undertaken by the water 91 
industry to assist the UK in meeting its obligations under the WFD to monitor concentrations of 92 
priority chemicals including APIs in WwTW influent, intermediate processes and effluent as well as 93 
assessing their risk to receiving waters (Gardner et al., 2013). The first phase of the CIP (named CIP1 94 
here) was a project that ran from 2012-2015 with one of its aims to investigate the fate of trace 95 
substances (including 11 APIs) in influent, effluent and intermediate WwTW processes of 25 WwTW. 96 
Some of results from this program have been reported previously (Gardner et al., 2012, Gardner et al.; 97 
2013, Jones et al.; 2013 and Comber et al., 2014). The £140 million investment in the second phase of 98 
the CIP (labelled CIP2 in this work) program builds on the outputs from CIP1 but extends the range 99 
of WwTW monitored and the number of determinands in order to in some cases measure (for WFD 100 
priority substances and priority hazardous substances) and in some cases predict (for emerging 101 
chemicals such as APIs) the impact on receiving waters. The CIP2 determinands include 19 APIs and 102 
4 metabolites at currently 45 WwTW on 20 occasions. In total, over 60 000 samples are to be taken, 103 
with over 2 million determinations. This study reports on the findings for APIs from the CIP1 and 104 
CIP2 programmes. 105 
 106 
WwTWs are primarily designed to serve the purpose of removing pathogens, suspended solids and 107 
gross organic and inorganic matter, rather than the removal of the increasing numbers of modern 108 
chemicals generally present in the µg/l range or less (Melvin, 2016). It has also been observed that 109 
there is a wide variation in removal rates for different substances, both within and between WwTWs. 110 
This difference in removal rate creates large uncertainty factors for the prediction and modeling of 111 
effluent concentrations and therefore creates a challenge in conducting meaningful risk assessments. 112 
There are currently no statutory consents applied to APIs in WwTW effluent, however, there is an 113 
urgent need to better understand the risk posed by APIs in effluents to receiving waters in order to 114 
inform future investment and to design and implement better risk assessment (Gardner, 2013). The 115 
presence of APIs is not measured on a routine basis for most WwTWs owing to cost and lack of 116 
legislative drivers. Consequently, there are a number of previous studies modelling the impact of APIs 117 
based on consumption, WwTW removal and dilution but the cost of analysis generally prevents the 118 
actual measurement of APIs in effluent (Johnson et al., 2013a,b; 2015).  119 
 120 
This study utilizes CIP 1 (11 APIs, from 25 WwTW sampled on up to 15 occasions) and the more 121 
recent CIP2 program (19 parent APIs and 4 metabolites, from WwTW sampled on 20 occasions). 122 
Although the APIs studied represent only a fraction of the total APIs in use, financial and practical 123 
constraints associated with sampling, preservation, analysis and replication meant the number of 124 
determinands needed to be controlled. However, APIs were prioritised on potential risk to the aquatic 125 
environment and all of the main classes of API have been represented (Table A1). Concentrations in 126 
the WwTW effluent have been compared with derived PNECs in receiving waters in order to generate 127 
a priority list of APIs of potential concern.   128 
 129 
2. MATERIALS AND METHODS 130 
2.1 Selection of Pharmaceuticals 131 
The selection of chemicals for CIP1 is discussed elsewhere (Gardner et al., 2012). The list of 132 
candidate APIs for inclusion in CIP2 was based primarily on a prioritization study undertaken by 133 
UKWIR in 2014 (UKWIR, 2014). Unlike many previous prioritisations, which focused on usage and 134 
concentrations detected in surface waters/effluents, problem sites or substances, this study adopted a 135 
risk assessment approach by comparing the estimated environmental concentrations of nearly 150 136 
pharmaceuticals (screened on usage and perceived hazard from a list of thousands of candidate 137 
substances) with data for their respective effect concentrations on a variety of receptor organisms in 138 
the aquatic environment.  139 
 140 
For the purposes of CIP2, this list was further refined by selection of substances that were considered 141 
to have the greatest potential as candidate WFD priority substances. The criteria for this selection 142 
were a) that the risk characterisation ratio (predicted concentration divided by the highest probable no 143 
effect concentration (PEC/PNEC) ranked higher than 1 in the overall 2014 UKWIR prioritisation and 144 
b) that the data supporting the  derivation of a PNEC were relatively reliable and complied with the 145 
WFD approach to PNEC derivation (EU 2011). In effect, this meant that PNECs were derived using 146 
experimental rather than modelled effects, long-term effects in organisms from different trophic levels 147 
were available (though short term exposure was also considered) and assessment factors were applied 148 
according to WFD guidance (EU 2011).  149 
 150 
The APIs prioritised were then further reviewed for their relevance to wastewater treatment, and the 151 
likelihood that the substance might be present in sewage effluents and hence discharged to surface 152 
waters (rather than being partitioned to sewage sludge). This resulted in the list of substances 153 
tabulated in Table A1 of the Electronic Supplementary Information (ESI). For the purposes of 154 
estimating risks, the PNEC values derived in the UKWIR prioritization (UKWIR 2014) were then re-155 
examined and (where available) they were substituted with the latest estimates derived by the EU 156 
Joint Research Centre (JRC, 2015), by the pharmaceutical industry (Astra Zeneca, 2016; NSF, 2016) 157 
or published in the open literature (Murray-Smith et al., 2012). Where no PNEC was available from 158 
these sources, the ecotoxicology data applied in deriving the PNECs reported by UKWIR (UKWIR 159 
2014) were used to deterministically estimate PNECs, according to WFD guidance (EU 2011) (Table 160 
2 and ESI Table A1). It is recognized that as new ecotoxicity data becomes available, substance 161 
PNECs are subject to update, and the estimates of PNECs applied in the present study may not, in 162 
every case, reflect the most up to date applied or proposed PNEC for regulatory purposes (e.g. under 163 
the WFD or European Medicines Agency (EMA) Environmental Risk Assessments. However, the 164 
estimated PNECs reported here were applied in the CIP for the purposes of selection for monitoring, 165 
preliminary risk assessment and prioritization, and so remain relevant in this context, and it is beyond 166 
the objectives of the present study to derive new PNECs for each of the APIs monitored. 167 
 168 
2.2 Sampling programme  169 
 170 
WwTWs were selected for the CIP program on the basis of broadly representing the distribution of 171 
UK WwTWs (A1, ESI), predominantly activated sludge plants (ASP) and trickling biofilters (TF) but 172 
also Membrane bioreactors (MBR) and oxidation ditches (OD) (Table A2 of ESI). 173 
 174 
 175 
 176 
Data used for this research were (Table A2 of ESI): 177 
 CIP1 program: 25 WwTW data for primary, secondary and tertiary process for 11 APIs. 178 
Sampling for this element of the programme was conducted over a two-year period between 179 
2011 and 2013. In this part of the programme two samples (spaced more than 4h apart to 180 
provide a degree of replication) were taken on between 10 and 15 occasions.  181 
 CIP2 program: 19 APIs and 4 metabolites were sampled on 20 occasions at 45 WwTWs in 182 
the influent and effluent (not intermediate process stages, unlike CIP1) over a two-year period 183 
between 2015 and 2017.  184 
Samples were collected on a stratified/random spot sampling basis (i.e. grab samples taken at discrete 185 
times rather than multiple integrated sampling), with sampling occasion spaced at approximately 186 
monthly intervals. A minimum of 15% of samples was taken at non-working hours (evenings and 187 
weekends) to ensure a wide a range possible of sampling intervals. 188 
 189 
2.3 Sampling and analysis 190 
The samples were collected in stainless steel samplers, stored in glass container and transported at 4° 191 
C to the analysis laboratories. The samples were stored a maximum of 5 days prior to analysis. This 192 
period was shown to be appropriate as not leading to more than a 20% change in determinand 193 
concentration; as confirmed before the start of the CIP sampling programme by undertaking tests of 194 
sample stability. Samples for the determination of steroid oestrogens were preserved by adding 30% 195 
hydrochloric acid and copper nitrate (Gardner, 2012). All analysis was by laboratories with ISO17025 196 
accreditation. Prior to the programme candidate laboratories were required to undertake tests of 197 
analytical performance to demonstrate that they met the stated programme requirements for limit of 198 
detection, precision and recovery in relevant sample matrices at relevant concentrations – that is, 199 
proof of performance was required, rather that methods being stipulated. Methods used for the 200 
determination of pharmaceuticals were all based on variants of High Performance Liquid 201 
Chromatograph–Mass Spectrometry (HPLC-MS) or Gas Chromatography-Mass Spectrometry (GC-202 
MS). Quality assurance/quality control (QA/QC) procedures, including the use of field blanks, were 203 
observed and reported for sample collection. Within laboratory QC sample pre-treatment and analysis 204 
for both laboratory tests and field sampling. Laboratories also took part in a bespoke proficiency 205 
testing scheme for pharmaceuticals. Details of the proficiency testing scheme used to ensure quality 206 
assurance is provided in A2 of the ESI. Where reported concentrations were below LOD (for the 207 
majority of substances apart from ibuprofen and tamoxifen this applied to fewer than 10% of the 208 
approximately 1000 results reported), the result was substituted at half face value - as stipulated in the 209 
relevant daughter Directive (EC, 2009) of the WFD. There were significant instances of inter-210 
laboratory bias or inter-regional variation, which would otherwise indicate if there was a bias in the 211 
procedure of sample handling and analysis methodology.  212 
 213 
 214 
Table 2. Determinand abbreviations and required limits of detection and total error  215 
  Concentration (µg/l)  
Code Determinand 
PNEC
1
  Required LOD 
effluent  
Required 
LOD river 
P%
2
  
ATNL Atenolol 148 0.01 0.01 50 
ATOV Atorvastatin   1.7 0.01 0.01 50 
ATOVo Ortho-hydroxy-atorvastatin  1.7 0.01 0.01 50 
ATOVp Para-hydroxy-atorvastatin  1.7 0.01 0.01 50 
AZMY Azithromycin 0.09 0.005 0.005 50 
CBAZ carbamazepine  2.5 0.1 0.1 50 
CBAZe 10,11- epoxy-carbamazepine 2.5 0.1 0.1 50 
CIPR Ciprofloxacin 0.089 0.01 0.01 50 
CLMY Clarithromycin  0.13 0.01 0.01 50 
DCF Diclofenac 0.05 0.01 0.01 50 
ERMY Erythromycin 0.2 0.1 0.1 50 
ERMYn Norerythromycin 0.2 0.1 0.1 50 
E1 Oestrone 0.003 0.001 0.001 50 
E2 17β oestradiol 0.001 0.0003 0.0003 50 
EE2 17α ethinyloestradiol 0.0001 0.00003 0.00003 50 
FLXT Fluoxetine 0.047 0.01 0.01 50 
IBPF Ibuprofen 0.01 0.01 0.01 50 
METF Metformin 13.45 0.1 0.1 50 
PRPL Propranolol 0.1 0.01 0.01 50 
RNTD Ranitidine  0.31 0.1 0.1 50 
SERT Sertraline 0.121 0.01 0.01 50 
SERTn Norsertraline 0.121 0.01 0.01 50 
TMXF Tamoxifen 0.49 0.005 0.005 50 
1 
Estimated PNEC (ESI Table 1). 
2
The target maximum tolerable error is equal to:  216 
 [(𝑡𝑎𝑟𝑔𝑒𝑡𝐿𝑂𝐷)2 + (
𝐴×𝑃%
100
)
2
]
1
2
 217 
 218 
Where the target maximum LOD and P% are given in the table and A is the determinand concentration in the 219 
sample. Performance testing should seek to demonstrate that the tolerable total error limit is achieved by 220 
showing that precision (2 x standard deviation) and bias are respectively no larger than half the target maximum 221 
total error. Thus, for example, for a total error limit of 100 units, standard deviation should be shown not to be 222 
larger than 25 and bias should not exceed 50. LOD was defined as 3.3x the standard deviation of blank-223 
corrected results of determinations made on a sample containing essentially no determinand (where possible in a 224 
relevant sample matrix) (Thompson and Ellison, 2013) In many cases, it was not possible to find effluent 225 
samples free from determinands in which case a synthetic sample was used.)  226 
 227 
2.4 Data handling and analysis 228 
The data handling and the statistical analysis were conducted with either Microsoft Excel (2016) or 229 
IBM SPSS Statistics software (version 20).  230 
 231 
In the data handling, the replicates were averaged and this value was then used for further statistical 232 
calculations. Mean, median, maximum, minimum and percentiles were calculated from the daily 233 
average. Fraction remain was calculated from the influent concentration as a fraction of the various 234 
stages of the process. The removal was calculated as percentage from the concentration (C):  235 
 236 
Removal (%) = (Cinfluent-Ceffluent)/ Cinfluent  237 
 238 
For the purpose of this research the term ‘removal’ relates to the loss of specified compounds from 239 
the aqueous phase between influent and effluent (and intervening process steps where quoted). It 240 
should be noted that the term removal does not necessarily mean degradation of the API; the loss of 241 
the parent compound may be a result of a combination of partitioning to particulates and/or 242 
degradation to metabolites.  243 
 244 
2.5 Risk assessment approach 245 
2.5.1 Face value risk ranking 246 
A “face value” exceedance is one in which the mean effluent concentration is greater than the relevant 247 
estimated PNEC; a “high confidence” exceedance is one for which the lower part of the 90% 248 
confidence interval about the mean effluent concentration is greater than the estimated PNEC i.e. 249 
there is 95% confidence that the mean is larger than the estimated PNEC.  250 
 251 
2.5.2 Refined risk assessment based on estimated available dilution 252 
Previous research has used a combination of modelled average river flows (Comber et al., 2013) and 253 
average WwTW discharge volumes to estimate dilution of effluent with receiving water. Effluent 254 
flow data was derived from measured values for larger WwTW, but estimated for works serving less 255 
than 2000 population equivalent based on water company estimates of connected population and 256 
per capita wastewater discharge to sewer (200 l/head/day- including an allowance for runoff) 257 
(Comber et al., 2007). A matrix (Table 3) of available dilution was then generated. 258 
 259 
  260 
Table 3.      Estimated dilutions available for UK WwTW 261 
 262 
 
Dilution ratio band  Total 
no. 
works 
 
0-1 1-2 2-5 5-10 10-15 15-20 20-50 50-100 100+ 
Midpoint dilution 1 1.5 3.5 7.5 12.5 17.5 35 75 100  
Combined dist’ dil’
1 
 0
2
 4.4 10.6 23.6 36.5 35 70 150 200  
Population served   
<250 86 75 54 54 11 21 86 86 2656 3127 
251-500 0 6 0 6 25 0 50 81 605 774 
501-2000 0 5 20 20 51 46 351 285 544 1322 
2001-10000 17 25 151 160 130 84 202 93 130 993 
10001-50000 82 67 160 103 24 30 48 15 18 548 
50001-200000 54 29 27 12 5 12 20 5 0 164 
200001-1m 74 0 11 0 0 0 0 0 0 85 
>1m 4 4 0 0 0 0 0 0 0 7 
Total 316 211 423 355 246 194 756 564 3954 7020 
% 5 3 6 5 4 3 11 8 56 
   1 Values used to calculate PECs in river using a Combined Distribution simulation (see A3 and Table 263 
A3). 2 A worst case scenario of zero dilution. 264 
 265 
The next step was to generate a cumulative percentile distribution of effluent concentration data (in 266 
10%ile intervals between 10 and 100%). This was achieved by averaging the effluent concentrations 267 
for each of the 45 WwTW sampled as part of the CIP2 survey. Step three was to divide each 268 
percentile concentration by the dilution available (using the value from the combined distribution 269 
estimate – See A3 of the ESI) to generate a PEC. The PEC can then be compared with estimated API 270 
PNECs to determine the number of WwTW at risk of exceeding the PNEC for any given each dilution 271 
band and percentile effluent concentration. An example of the risk assessment is provided in Table 272 
A4 of the ESI.      273 
 274 
3. RESULTS and DISCUSSION 275 
 276 
3.1 Removal efficiency for APIs  277 
 278 
The CIP1 study generated removal data for APIs across all stages of treatment, influent, after primary 279 
settlement, secondary biological treatment and where applied, post tertiary treatment. To gain a better 280 
understand of the fate of the 11 pharmaceuticals through the treatment train, the fraction of API 281 
remaining in the effluent after treatment was calculated across all 25 WwTW in the CIP1 program 282 
(Table 4). 283 
 284 
Each cycle of sampling was treated as an isolated entity (averaging the samples within the same day), 285 
thus simplify the ability to compare APIs removal across the diverse range of works. As seen from the 286 
data in Table 4, most APIs are removed in the secondary biological treatment process and very little 287 
through further tertiary treatment. This corresponds well with previously published data (Stockholm 288 
Vatten, 2010). The absolute effluent concentrations (Table 4) also correspond well with those reported 289 
elsewhere for predominantly UK effluents (Table 1).  290 
 291 
Table 4.  CIP1 data for API fraction remaining throughout the process stages in the WwTW, as 292 
well as the absolute effluent concentration 293 
 294 
 Fraction of API remaining in effluent after treatment  
API Primary Process Secondary Process Tertiary Process Effluent Concentration 
(µg/l)  
 Median 5-
%ile 
95-
%ile 
Median 5-
%ile 
95-
%ile 
Median 5-
%ile 
95-
%ile 
Median 5-%ile 95-%ile 
Diclofenac (DCF) 0.76 0.40 1.6 0.52 0.18 1.2 0.44 0.16 1.0 0.20 0.084 0.51 
Erythromycin 
(ERMY) 
0.79 0.26 1.7 0.52 0.11 1.2 0.44 0.08 1.1 0.43 0.052 2.0 
Ethinylestradiol 
(EE2) 
0.96 0.36 2.4 0.54 0.13 1.9 0.49 0.10 3.5 0.0003 0.0001 0.0020 
Oestrone (E1) 1.0 0.59 2.1 0.28 0.02 2.4 0.10 0.01 1.2 0.0048 0.0007 0.058 
Oestradiol (E2) 0.97 0.44 1.6 0.11 0.01 0.8 0.05 0.01 0.80 0.0009 0.0001 0.012 
Fluoxetine (FLXT) 0.79 0.38 1.5 0.48 0.08 1.2 0.46 0.09 1.1 0.032 0.0050 0.066 
Ibuprofen (IBPF) 0.83 0.39 1.3 0.04 0.00 0.2 0.01 0.00 0.21 0.19 0.0050 2.9 
Ofloxacin (OFLX) 0.88 0.12 2.2 0.45 0.08 1.4 0.34 0.05 1.0 0.016 0.0050 0.14 
Oxytetracycline 
(OXTCY) 
0.66 0.13 1.6 0.16 0.00 0.6 0.13 0.01 0.54 0.21 0.019 1.1 
Propranolol 
(PRPL) 
0.91 0.52 1.4 0.68 0.14 1.2 0.65 0.16 1.2 0.14 0.042 0.32 
Salicylic acid 
(SLCYA) 
0.85 0.28 1.6 0.01 0.00 1.1 0.01 0.00 0.33 0.18 0.017 3.8 
 295 
 296 
ERMY, DCF, FLXT and OXTCY were all shown to have similar removal efficiencies throughout the 297 
primary and secondary treatment processes based on the CIP1 dataset. The primary process relies 298 
mostly on removal of APIs through adsorption onto sludge (Stockholm Vatten, 2010) as retention 299 
times are relatively low and so this fits well to the data found for OXTCY, as it is previously known 300 
to adsorb strongly onto solids (Verlicchi, 2012) and found at higher concentration (4 mg/kg) in sludge 301 
compared with other APIs such as DCF, ERMY and FLXT (0.07, 0.05 and 0.12 mg/kg, respectively) 302 
(Jones et al., 2014). PRPL had overall poor removal of 35% and 26% (0.65 and 0.74 fraction 303 
remaining) between influent and effluent for CIP1 and CIP2 respectively (Table 4 and 5), which also 304 
corresponded well with previously published data of 28% removal efficacy (0.72 fraction remaining) 305 
in WwTW (Kasprzyk-Hordern et al., 2008). 306 
 307 
In the CIP2 data set (Table 5) there was high total removal (based on comparison of influent and 308 
effluent API concentrations) of IBPF, METF, E2, ATNL, ATOVp, E1, ATOV, CIPR, ATOVo, which 309 
all had fraction remaining ratios of 0.2 or lower (i.e. better than 80% removal efficiency) (Figure 1, 310 
and Table A5). This suggested either rapid biodegradation of the parent compound and/or adsorption 311 
to sludge. None of the substances are considered sufficiently volatile to suggest any significant loss to 312 
the atmosphere. The intermediate set of APIs consisting of SERTn, RNTD, CLMY, EE2, FLXT, DCF 313 
and ERMY, which all had fraction remaining below 0.6 (i.e. greater than 40% removal efficiency). 314 
PRPL, CBAZe, ERMYn, AZMY and CBAZ all showed poor removal through the WwTW process 315 
(Figure 1 and Table A5).   316 
 317 
Figure 1.       Fractional removal for APIs in CIP2 318 
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Table 5. Summary concentration values for CIP2 APIs (45 WwTW sampled on 20  occasions) 321 
 322 
 Influents (µg/l)  Effluents (µg/l) 
Substance 
Median of 
WwTW 
average 
values  25%ile 75%ile  
Median of 
WwTW 
average 
values  25%ile 75%ile 
E1 0.038 0.030 0.049 
 
0.004 0.002 0.014 
E2 0.014 0.011 0.019 
 
0.001 0.0003 0.002 
EE2 0.00051 0.00041 0.00097 
 
0.00020 0.00014 0.00040 
DCF 0.54 0.40 0.76 
 
0.29 0.20 0.41 
IBPF 18.13 12.08 21.32 
 
0.11 0.02 0.56 
ATOV 0.61 0.41 1.01 
 
0.10 0.06 0.16 
ATOVo 1.33 0.81 1.76 
 
0.17 0.08 0.29 
ATOVp 1.33 0.82 2.03 
 
0.21 0.12 0.35 
PRPL 0.260 0.171 0.354 
 
0.174 0.119 0.245 
ATNL 2.600 1.872 3.297 
 
0.323 0.210 0.463 
ERMY 0.733 0.551 1.161 
 
0.350 0.190 0.558 
ERMYn 0.060 0.050 0.091 
 
0.050 0.027 0.050 
AZMY 0.351 0.171 0.748 
 
0.202 0.095 0.425 
CLMY 0.953 0.684 1.564 
 
0.400 0.265 0.711 
CIPR 0.861 0.385 1.510 
 
0.147 0.067 0.276 
METF 129 104 208 
 
4.8 1.7 15 
RNTD 2.35 1.68 3.06 
 
0.529 0.286 0.730 
CBAZ 0.60 0.43 0.84 
 
0.641 0.477 0.756 
CBAZe 0.18 0.11 0.42 
 
0.117 0.072 0.292 
SERT 0.18 0.12 0.27 
 
0.063 0.037 0.081 
SERTn 0.12 0.10 0.21 
 
0.033 0.016 0.045 
FLXT 0.10 0.07 0.15 
 
0.051 0.036 0.079 
TMXF 0.0034 0.0026 0.0047 
 
0.0025 0.0025 0.0028 
TXP 0.0050 0.0028 0.0052 
 
0.0050 0.0026 0.0050 
BZT 2.16 1.60 3.97 
 
1.38 1.08 2.62 
TZT 1.59 1.19 2.60 
 
1.27 0.88 1.96 
 323 
 324 
Figure 2 below represents mean concentrations in the influent and effluent for selected APIs with the 325 
others shown in Figure A2 and demonstrates the degree of variability for APIs between WwTW.     326 
 327 
 328 
 329 
 330 
 331 
Figure 2.  Graphic representation of mean concentrations of APIs in influent and effluent of 332 
individual CIP2 WwTWs 333 
 334 
In some cases there appears to be an increase in API concentrations in the effluent compared with the 335 
influent (Figure 2 and A2 of ESI). There are three main reasons for this:  336 
1) The hydraulic retention time (HRT) within a WwTW means that samples of influent and 337 
effluent collected at the same time (a practical requirement of the work) may not reflect actual 338 
removal efficiency owing to within works management practices, e.g. batch flow, sludge 339 
return pumping, taking place at the time of sampling. Given HRTs vary vastly between works 340 
and types of works it was not practical to calculate nor practically sample WwTW based on 341 
their HRTs.    342 
2) The APIs were detected at ng/l levels in a highly complex matrix (particularly the influent) 343 
therefore analytical errors may lead to apparent increase in concentrations during treatment 344 
(Jelic et al., 2011). 345 
3) In some cases this is a real effect, for example E1 is a degradation product of E2 (Heffley et 346 
al., 2014) and so if the rate of loss of E1 during treatment is less than that of E2, then an 347 
apparent increase in E1 will occur.  348 
 349 
3.2 What is the environmental risk of the APIs being discharged in WwTW effluent? 350 
The median and interquartile concentration values of pharmaceuticals in influents and effluents are 351 
summarised in Table 5. Figure 3 shows a summary risk ranking of the CIP pharmaceutical group of 352 
substances in relation to the estimated predicted no-effect concentrations applied in CIP (CIP 353 
PNECs). A “face value” exceedance is one in which the mean effluent concentration is greater than 354 
the relevant estimated PNEC; a “high confidence” exceedance is one for which the lower part of the 355 
90% confidence interval about the mean effluent concentration is greater than the estimated PNEC i.e. 356 
there is 95% confidence that the mean is larger than the estimated PNEC. Substances not shown do 357 
not figure as noteworthy exceedances.  358 
 359 
 360 
Figure 3.  Risk ranking of CIP2 APIs  361 
 362 
Figure 3 above illustrates the severity of potential non-compliances for pharmaceuticals as the ratio of 363 
the observed concentrations in effluents to the relevant estimated PNEC. This ratio represents the 364 
dilution that would be required to achieve compliance, assuming zero upstream concentrations. An 365 
important proportion of UK wastewater treatment discharges are not subject to very much greater than 366 
a twofold dilution so the potential for downstream non-compliance with PNEC values does exist on 367 
the basis of a single effluent discharge alone. Table 3 shows that over 500 WwTW has estimated 368 
dilutions of less than 2, 8% of all the WwTW in the UK. Added to this concern must be a 369 
consideration of the pharmaceutical concentrations already present in a receiving watercourse 370 
upstream of the discharge. Whilst the CIP2 programme did not include the determination of 371 
pharmaceuticals in upstream river samples such analysis was undertaken for a range of Priority 372 
Substances, including trace organic compounds that like pharmaceuticals, are primarily discharged as 373 
a result of domestic inputs to wastewater. The evidence obtained from these investigations is that the 374 
burden of upstream contamination is far from irrelevant and that discharges in the higher parts of a 375 
river catchment, for example from septic tanks and small WwTW, can raise concentrations to values 376 
that subsequent discharges lower in the catchment only serve to maintain (Phillips et al., 2015). This 377 
is an aspect that deserves careful future examination in the context of pharmaceuticals.  378 
 379 
Figure 4 shows that several pharmaceuticals have been shown to be present in effluents at 380 
concentrations close to, or in many cases in excess of, values that might form the basis of future 381 
regulatory limit values.  382 
 383 
 384 
 385 
 386 
Figure 4.   Required within river dilution of WwTW effluent for API concentrations to be 387 
                    less than  their estimated PNEC.  388 
                       Note median effluent concentration for ibruprofen (IBPF) as a ratio of estimated PNEC is 11.  389 
 390 
Applying a more realistic risk assessment using estimates of available dilution for UK WwTW 391 
effluents discharged to receiving waters, combined with the measured API concentrations from the 392 
CIP2 dataset generates a similar priority ranking list in terms of the number of WwTW potentially 393 
exceeding downstream estimated PNECs after the effluent has mixed with receiving water (Figure 5). 394 
For IBPF this equates to 890 WwTW or 13% of all WwTW in the UK. This estimate is also based on 395 
the assumption that there are no significant inputs of API upstream of the WwTW in question.  396 
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  398 
Figure 5.   Number of WwTW at risk of exceeding estimated PNEC downstream of receiving 399 
                  water  400 
 401 
DCF, AZMY, CLMY, EE2, PRPL, CIPR, RNTD and E1 are all predicted to exceed downstream 402 
PNECs in over 200 WwTW. Required mean removal efficiency for any tertiary treatment would 403 
range from 35% to 61% depending on the API (Table A6 of ESI). Whether the same tertiary treatment 404 
technology could be applied to all of the APIs largely depends on their physico-chemical 405 
characteristics. The use of granulated activated carbon (GAC) would require an API to have a 406 
reasonable affinity for carbon (i.e. a relatively high octanol:water coefficient - logKow) which may 407 
not always be the case for APIs with a high degree of polarity, particularly those that are charged at 408 
typical effluent pH (pH 7.5) which would include DCF, IBPF, ATOV and to a degree CIPR (pKa = 409 
6.09). Furthermore, as can be seen from Figures 1 and 2, there are considerable variations in the 410 
removal rates between WwTW and so it may be expected to observe a similarly wide variation in 411 
removal rates and/or final effluent API concentration, if additional tertiary treatment were to be 412 
applied. This would obviously lead to a degree of uncertainty regarding possible compliance with any 413 
given in river PNEC or water quality standard. 414 
 415 
Figures 1 and 2 show that WwTW in general, have a high (but variable) removal rate for most 416 
substances with only E2, EE2 propranolol, the macrolide antibiotics, carbamazepine fluoxetine and 417 
tamoxifen exhibiting poor removal. It is clear (and unsurprising) that more complex factors, such as 418 
the contaminant load on the WwTW, residence time in the works, overall strength of the influent, 419 
questions of operation and maintenance as well as the presence of absence of tertiary treatment “add-420 
ons”, combine at each location to result in the observed treatment performance (Zorita et al., 2009; 421 
Le-Minh et al., 2010; Deegan et al., 2011). In the wider context, the persistence of pharmaceuticals in 422 
surface waters will be determined by the degree of upstream contamination from other (in this case, 423 
presumably WwTW) inputs higher in the river catchment. As has been seen in elements of the CIP2 424 
programme dealing with Priority Substances, upstream contamination and lack of headroom for 425 
downstream discharges can often be more important than the local impact of a given WwTW. The 426 
likely importance of upstream inputs for pharmaceuticals is unclear. Whilst upstream inputs are 427 
inevitable in all sites except those at the top of catchments (where there may still be influences from 428 
septic tanks) the effect of such inputs is not known, but if smaller WwTW are less efficient than the 429 
predominantly larger works selected for the CIP programmes, then the risk to surface waters of 430 
exceeding estimated PNECs for APIs may be significant. Persistence and the degree and rate of 431 
breakdown in the environment are critical in this context. To fulfil their purpose pharmaceuticals need 432 
to be absorbed by the patient, to remain for sufficient time to have the desired effect and then be 433 
excreted. This means that in terms of their structure and hence fate and behaviour, pharmaceuticals 434 
tend to occupy a middle ground between substances on the one hand that are non-polar, hydrophobic, 435 
insoluble, and persistent and those that are highly polar, soluble, mobile and relatively readily 436 
biodegradable. This suggests that some degree of degradation in-river might mean that input of 437 
pharmaceuticals upstream may not be as great a risk as it is for other persistent, highly mobile priority 438 
substances such as some metals, persistent pesticides and industrial compounds.  439 
 440 
It should, however, be noted that this assessment is based on the mixing of single APIs in effluent and 441 
receiving water under average flow conditions for a fraction of the APIs currently available and used. 442 
During summer months river flows are significantly lower than average values, yet effluent flows will 443 
remain relatively stable (accepting rain events contributing to flow in combined sewerage systems) 444 
leading to generally lower dilution available and therefore higher concentrations of effluent derived 445 
contaminants in receiving waters. Seasonal pattern of use for some APIs, antihistamines in summer, 446 
flu vaccines in winter etc, would also lead to a variable distribution of APIs in WwTW effluent and 447 
hence variable risk to receiving waters. The potential risk of mixtures is complex and requires detailed 448 
knowledge of ecotoxicology for the APIs of interest. Such assessments along with determining 449 
temporal variations in risk, require more a significantly detailed dataset (not necessarily currently 450 
available) and as such is beyond the scope of this broader risk assessment.     451 
 452 
Whilst the objective of this research has not been to estimate costs for compliance, drawing on 453 
previous estimates of costs for API treatment based on fitting sand filters and granulated carbon 454 
sorption technology, the whole life cost (based on 2007 data) for achieving downstream compliance 455 
with the estimated IBPF PNEC would approximately £9bn (Comber et al., 2007). So for illustrative 456 
purposes it is evident that achieving compliance for all API estimated PNECs would be a substantial 457 
investment by the water industry. These estimates are only based on mixing downstream of receiving 458 
water and effluent and do not take account of any biodegradation or sorption to particulates leading to 459 
reduced exposure which would need to be considered as part of a more detailed risk assessment prior 460 
to considering any remedial action regarding removal of APIs from WwTW effluent.   461 
 462 
Much in relation to future compliance (and therefore cost to the water companies) will depend on the 463 
derivation method and data used to set water quality standards. The outputs of the CIPs in this case 464 
constitute a valuable risk assessment of the likely impact of whatever regulations might be introduced 465 
in the future. Of the pharmaceuticals / likely future Priority Substances, the so-called WFD watch list 466 
substance diclofenac, the steroids as well as possibly ibuprofen appear to be at risk of causing 467 
widespread exceedances of estimated PNECs in UK rivers. With respect to these substances, options 468 
of regulated use and control of patient behaviour relating to disposal of unused medicines might be 469 
enough to make a substantial difference. However, wastewater treatment solutions might turn out to 470 
be essential for the steroids, at least in the case of EE2.  471 
 472 
4. CONCLUSIONS  473 
As has been observed for the CIP1 program there are a high variability in the removal of APIs 474 
observed between and within the individual plants. This variation may be due to many factors such as 475 
process technology as well as regional variation. Rates of removal in wastewater treatment have also 476 
been determined. The majority of substances studied are removed to a high degree, but with a wide 477 
variation in performance. Those that are less substantially reduced in concentration are 478 
ethinyloestradiol, diclofenac, propranolol, the macrolide antibiotics, fluoxetine, tamoxifen and 479 
carbamazepine. All except the last two of these substances are present in effluents at concentration 480 
higher than their estimated respective PNECs.  481 
 482 
If the PNECs applied in the present study were all implemented as regulatory quality standards under 483 
the WFD, the risk assessment undertaken suggests that over a 10 times dilution would be required, to 484 
ensure that some APIs (ibuprofen in this case) meet their downstream quality standards, assuming no 485 
upstream contribution to background concentrations. This could entail treatment at up to 890 WwTW 486 
to meet current PNECs.   487 
 488 
Much in relation to the need for future action by dischargers depends on whether or not these 489 
substances are regulated and the water quality standard chosen, but if the CIP estimated PNECs are a 490 
guide to regulatory limits, then there is potential for localised non-compliance in surface waters; at 491 
least in the case of ethinyloestradiol, diclofenac, ibuprofen, propranolol and the macrolide antibiotics. 492 
Further monitoring of pharmaceuticals in surface waters to determine the temporal variations in river 493 
concentrations associated with changing river flows (and hence dilution), the persistence, and the 494 
bioavailability of APIs needs to be considered. 495 
 496 
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